Evolution of radio sensibilization methods in radiotherapy of malignant tumors
O. S. Plotnikova,
V. I. Apanasevich,
P. A. Knyazenko,
A. A. Shestakova,
V. P. Karlina,
P. G. Korenkov https://doi.org/10.34215/1609-1175-2021-2-14-18
Abstract
Publications survey devoted to the usage of radio sensitizers for radiation therapy of the tumors is demonstrated. Currently such radiomodification agents as platinum, fluorouracil, gold, gadolinium, iodine, etc. are widely used in oncology. General application methods and ways of introducing heavy metals compounds are highlighted. Their influence on the indexes of the acute and chronic toxicity among patients suffering malignancies is estimated.
About the Authors
O. S. Plotnikova
Pacific State Medical University;
Primorsky Regional Oncological Dispensary
Russian Federation
Russian Federation
MD; PhD student
2 Ostryakova Ave., Vladivostok, 690002, Russian Federation
V. I. Apanasevich
Pacific State Medical University;
Primorsky Regional Oncological Dispensary
Russian Federation
Russian Federation
MD, PhD, professor, Institute of Surgery
2 Ostryakova Ave., Vladivostok, 690002, Russian Federation
P. A. Knyazenko
Vladivostok Clinical Hospital No. 1
Russian Federation
Russian Federation
MD
22 Sadovaya St., Vladivostok, 690078, Russian Federation
A. A. Shestakova
Pacific State Medical University
Russian Federation
Russian Federation
student,
92 Ostryakova Ave., Vladivostok, 690002, Russian Federation
V. P. Karlina
Pacific State Medical University
Russian Federation
Russian Federation
student
92 Ostryakova Ave., Vladivostok, 690002, Russian Federation
P. G. Korenkov
Pacific State Medical University
Russian Federation
Russian Federation
student
92 Ostryakova Ave., Vladivostok, 690002, Russian Federation
References
1. Ulyanenko SE, Polityukova NA. Radimodifying effect of hyperglycemia, glucose and tumor dose dependence. Medical Radiology. 1991;1:21–3 (In Russ).
2. Mufazalov FF, Nabuillina MK, Loskutov LA. The use of metronidazole in radiation therapy for bladder cancer. Medical Radiology. 1992; 3–4:21–3 (In Russ).
3. Bleehen MN. Lung cuncer – still a long road ahead. Brit J Cancer. 1990;61:493–4.
4. Cole D.J., Jones A.C. The treatment of locally advanced carcinoma of the cervix with radiation, 5-fluorouracil and mitomycin C. Brit J Cancer. 1993;66:52.
5. Micksche M. Interferon-ein neues therapeutisches prinzip. Wien Med Wochens Chr. 1993;143(16–17):408–12.
6. Maksimov SYa, Guseinov KD. Combined treatment for cervical cancer. Practical Oncology. 2002;3(3):200–10 (In Russ).
7. Gastrointestinal Tumor Study Group. Prolongation of the diseasefree interval in surgically treated rectal carcinoma. New Engl J Med. 1985;312:1465–72.
8. Krook JE, Moeretel CG, Gunderson L.L., Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. New Engl J Med. 1991;324:709–15.
9. National Institutes of Health Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264:1444–50.
10. Dvornichenko VV, Afanasyev SG, Shelekhov AV, Moskvina NA. Radiation therapy in combination therapy for rectal cancer: A literature review. Siberian Journal of Oncology. 2009;1:72–7 (In Russ).
11. Joiner M, van der Kogel A, eds. Basic Clinical Radiobiology. Moscow: Laboratoriya Znaniy; 2014 (In Russ).
12. Wolmark N., Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92(5):388–96.
13. Allegra CJ, Yothers G, O’Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or Capecitabine plus radiation with or without Oxaliplatin in rectal cancer patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst. 2015;107(11):djv248. doi: 10.1093/jnci/djv248.
14. Louafi S, Mansourbakht T, Bonyhay L, Taïeb J. Oxaliplatine en oncologie digestive en dehors du cancer colorectal [Oxaliplatin in gastro-intestinal tract cancer except colorectal cancer]. Bull Cancer. 2006;93(Suppl 1):S23–33.
15. Hofheinz RD, Arnold D, Fokas E, Kaufmann M, Hothorn T, Folprecht G, et al. German Rectal Cancer Study Group. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: A post hoc analysis of the CAO/ARO/AIO-04 phase III trial. Ann Oncol. 2018;29(8):1793–9.
16. Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): Final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–89.
17. van Dijk TH, Tamas K, Beukema JC, Beets GL, Gelderblom AJ, de Jong KP, et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol. 2013;24(7):1762–9.
18. Punushapai U, Yuenyao P, Chumworathayi B, Luanratanakorn S, Udomthavornsuk B. Weekly cisplatin 20 mg/m2 in patients with carcinoma of cervix receiving pelvic radiotherapy at Srinagarind Hospital: A randomized controlled trial. Asian Pac J Cancer Prev. 2010;11(1):201–7.
19. Spinelli A, Girelli M, Arosio D, Polito L, Podini P, Martino G, et al. Intracisternal delivery of PEG-coated gold nanoparticles results in high brain penetrance and long- lasting stability. J Nanobiotechnology. 2019;17(1):49. doi: 10.1186/s12951-019-0481-3
20. Hwang C, Kim JM, Kim J. Influence of concentration, nanoparticle size, beam energy, and material on dose enhancement in radiation therapy. J Radiat Res. 2017;58(4):405–11.
Review
For citations:
Plotnikova O.S., Apanasevich V.I., Knyazenko P.A., Shestakova A.A., Karlina V.P., Korenkov P.G. Evolution of radio sensibilization methods in radiotherapy of malignant tumors. Pacific Medical Journal. 2021;(2):14-18. (In Russ.) https://doi.org/10.34215/1609-1175-2021-2-14-18
Views:
378
Email this article 